The NKG2D downregulation in cancer patients has been correlated with high levels of circulating MICA/B molecules shed by the tumor burden [60], or with circulating mature TGF-β or to regulatory T cells expressing membrane bound TGF-β [60]–[62]. The gene discussed is TGFB1; the disease is neoplasm.